Yifan Peng1, Shazia Dharssi2, Qingyu Chen1, Tiarnan D Keenan3, Elvira Agrón3, Wai T Wong3, Emily Y Chew4, Zhiyong Lu5. 1. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland. 2. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland; National Eye Institute, National Institutes of Health, Bethesda, Maryland. 3. National Eye Institute, National Institutes of Health, Bethesda, Maryland. 4. National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov. 5. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Maryland. Electronic address: zhiyong.lu@nih.gov.
Abstract
PURPOSE: In assessing the severity of age-related macular degeneration (AMD), the Age-Related Eye Disease Study (AREDS) Simplified Severity Scale predicts the risk of progression to late AMD. However, its manual use requires the time-consuming participation of expert practitioners. Although several automated deep learning systems have been developed for classifying color fundus photographs (CFP) of individual eyes by AREDS severity score, none to date has used a patient-based scoring system that uses images from both eyes to assign a severity score. DESIGN: DeepSeeNet, a deep learning model, was developed to classify patients automatically by the AREDS Simplified Severity Scale (score 0-5) using bilateral CFP. PARTICIPANTS: DeepSeeNet was trained on 58 402 and tested on 900 images from the longitudinal follow-up of 4549 participants from AREDS. Gold standard labels were obtained using reading center grades. METHODS: DeepSeeNet simulates the human grading process by first detecting individual AMD risk factors (drusen size, pigmentary abnormalities) for each eye and then calculating a patient-based AMD severity score using the AREDS Simplified Severity Scale. MAIN OUTCOME MEASURES: Overall accuracy, specificity, sensitivity, Cohen's kappa, and area under the curve (AUC). The performance of DeepSeeNet was compared with that of retinal specialists. RESULTS: DeepSeeNet performed better on patient-based classification (accuracy = 0.671; kappa = 0.558) than retinal specialists (accuracy = 0.599; kappa = 0.467) with high AUC in the detection of large drusen (0.94), pigmentary abnormalities (0.93), and late AMD (0.97). DeepSeeNet also outperformed retinal specialists in the detection of large drusen (accuracy 0.742 vs. 0.696; kappa 0.601 vs. 0.517) and pigmentary abnormalities (accuracy 0.890 vs. 0.813; kappa 0.723 vs. 0.535) but showed lower performance in the detection of late AMD (accuracy 0.967 vs. 0.973; kappa 0.663 vs. 0.754). CONCLUSIONS: By simulating the human grading process, DeepSeeNet demonstrated high accuracy with increased transparency in the automated assignment of individual patients to AMD risk categories based on the AREDS Simplified Severity Scale. These results highlight the potential of deep learning to assist and enhance clinical decision-making in patients with AMD, such as early AMD detection and risk prediction for developing late AMD. DeepSeeNet is publicly available on https://github.com/ncbi-nlp/DeepSeeNet.
PURPOSE: In assessing the severity of age-related macular degeneration (AMD), the Age-Related Eye Disease Study (AREDS) Simplified Severity Scale predicts the risk of progression to late AMD. However, its manual use requires the time-consuming participation of expert practitioners. Although several automated deep learning systems have been developed for classifying color fundus photographs (CFP) of individual eyes by AREDS severity score, none to date has used a patient-based scoring system that uses images from both eyes to assign a severity score. DESIGN: DeepSeeNet, a deep learning model, was developed to classify patients automatically by the AREDS Simplified Severity Scale (score 0-5) using bilateral CFP. PARTICIPANTS: DeepSeeNet was trained on 58 402 and tested on 900 images from the longitudinal follow-up of 4549 participants from AREDS. Gold standard labels were obtained using reading center grades. METHODS: DeepSeeNet simulates the human grading process by first detecting individual AMD risk factors (drusen size, pigmentary abnormalities) for each eye and then calculating a patient-based AMD severity score using the AREDS Simplified Severity Scale. MAIN OUTCOME MEASURES: Overall accuracy, specificity, sensitivity, Cohen's kappa, and area under the curve (AUC). The performance of DeepSeeNet was compared with that of retinal specialists. RESULTS: DeepSeeNet performed better on patient-based classification (accuracy = 0.671; kappa = 0.558) than retinal specialists (accuracy = 0.599; kappa = 0.467) with high AUC in the detection of large drusen (0.94), pigmentary abnormalities (0.93), and late AMD (0.97). DeepSeeNet also outperformed retinal specialists in the detection of large drusen (accuracy 0.742 vs. 0.696; kappa 0.601 vs. 0.517) and pigmentary abnormalities (accuracy 0.890 vs. 0.813; kappa 0.723 vs. 0.535) but showed lower performance in the detection of late AMD (accuracy 0.967 vs. 0.973; kappa 0.663 vs. 0.754). CONCLUSIONS: By simulating the human grading process, DeepSeeNet demonstrated high accuracy with increased transparency in the automated assignment of individual patients to AMD risk categories based on the AREDS Simplified Severity Scale. These results highlight the potential of deep learning to assist and enhance clinical decision-making in patients with AMD, such as early AMD detection and risk prediction for developing late AMD. DeepSeeNet is publicly available on https://github.com/ncbi-nlp/DeepSeeNet.
Authors: Allan Cerentini; Daniel Welfer; Marcos Cordeiro d'Ornellas; Carlos Jesus Pereira Haygert; Gustavo Nogara Dotto Journal: Stud Health Technol Inform Date: 2017
Authors: Alicja R Rudnicka; Zakariya Jarrar; Richard Wormald; Derek G Cook; Astrid Fletcher; Christopher G Owen Journal: Ophthalmology Date: 2011-12-15 Impact factor: 12.079
Authors: Frederick L Ferris; C P Wilkinson; Alan Bird; Usha Chakravarthy; Emily Chew; Karl Csaky; SriniVas R Sadda Journal: Ophthalmology Date: 2013-01-16 Impact factor: 12.079
Authors: Constance D Lehman; Robert D Wellman; Diana S M Buist; Karla Kerlikowske; Anna N A Tosteson; Diana L Miglioretti Journal: JAMA Intern Med Date: 2015-11 Impact factor: 21.873
Authors: Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong Journal: Lancet Glob Health Date: 2014-01-03 Impact factor: 26.763
Authors: Daniel S Kermany; Michael Goldbaum; Wenjia Cai; Carolina C S Valentim; Huiying Liang; Sally L Baxter; Alex McKeown; Ge Yang; Xiaokang Wu; Fangbing Yan; Justin Dong; Made K Prasadha; Jacqueline Pei; Magdalene Y L Ting; Jie Zhu; Christina Li; Sierra Hewett; Jason Dong; Ian Ziyar; Alexander Shi; Runze Zhang; Lianghong Zheng; Rui Hou; William Shi; Xin Fu; Yaou Duan; Viet A N Huu; Cindy Wen; Edward D Zhang; Charlotte L Zhang; Oulan Li; Xiaobo Wang; Michael A Singer; Xiaodong Sun; Jie Xu; Ali Tafreshi; M Anthony Lewis; Huimin Xia; Kang Zhang Journal: Cell Date: 2018-02-22 Impact factor: 41.582